- Home
- TLNC vs OCGN Comparison
TLNC vs OCGN Comparison
Compare TLNC & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLNC
- OCGN
- Stock Information
- Founded
- TLNC 2025
- OCGN 2013
- Country
- TLNC United States
- OCGN United States
- Employees
- TLNC N/A
- OCGN N/A
- Industry
- TLNC
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLNC
- OCGN Health Care
- Exchange
- TLNC Nasdaq
- OCGN Nasdaq
- Market Cap
- TLNC 338.8M
- OCGN 321.7M
- IPO Year
- TLNC 2025
- OCGN N/A
- Fundamental
- Price
- TLNC $10.14
- OCGN $1.19
- Analyst Decision
- TLNC
- OCGN Strong Buy
- Analyst Count
- TLNC 0
- OCGN 2
- Target Price
- TLNC N/A
- OCGN $7.00
- AVG Volume (30 Days)
- TLNC 969.0
- OCGN 3.3M
- Earning Date
- TLNC 01-01-0001
- OCGN 11-05-2025
- Dividend Yield
- TLNC N/A
- OCGN N/A
- EPS Growth
- TLNC N/A
- OCGN N/A
- EPS
- TLNC N/A
- OCGN N/A
- Revenue
- TLNC N/A
- OCGN $5,370,000.00
- Revenue This Year
- TLNC N/A
- OCGN N/A
- Revenue Next Year
- TLNC N/A
- OCGN N/A
- P/E Ratio
- TLNC N/A
- OCGN N/A
- Revenue Growth
- TLNC N/A
- OCGN 14.26
- 52 Week Low
- TLNC $9.98
- OCGN $0.52
- 52 Week High
- TLNC $11.04
- OCGN $1.90
- Technical
- Relative Strength Index (RSI)
- TLNC N/A
- OCGN 36.58
- Support Level
- TLNC N/A
- OCGN $1.14
- Resistance Level
- TLNC N/A
- OCGN $1.22
- Average True Range (ATR)
- TLNC 0.00
- OCGN 0.08
- MACD
- TLNC 0.00
- OCGN -0.01
- Stochastic Oscillator
- TLNC 0.00
- OCGN 28.79
About TLNC Talon Capital Corp. Class A Ordinary Shares
Talon Capital Corp is a newly organized blank check company.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").